Gyroscope Therapeutics Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Gyroscope Therapeutics Limited - overview
Established
2016
Location
London, -, UK
Primary Industry
Biotechnology
About
Based in London, UK, and founded in 2016, Gyroscope Therapeutics Limited operates as a clinical-stage gene therapy company that develops gene therapies for ocular diseases. The company was founded by Khurem Farooq. In March 2021, Gyroscope Therapeutics Limited raised its latest Series C funding from Forbion. Gyroscope Therapeutics Limited is a developer of a gene therapy GT005 a treatment for eye diseases.
Gyroscope Therapeutics Limited plans to use its funding from March 2021 to advance the clinical development of GT005 lead gene therapy. The company also plans to list on the Nasdaq under the symbol VISN.
Current Investors
Syncona , Cambridge Innovation Capital, Sofinnova Investments
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Optometrists & Opticians Products and Services
Website
www.gyroscopetx.com
Verticals
HealthTech
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.